Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University

A new publication in International Journal of Clinical Pharmacy on the New Medicine Service (NMS) for cardiovascular patients transitioning from hospital to primary care. Read the article here: https://rdcu.be/d23ZG The NMS proves to be an effective way to identify drug-related problems and support patients when starting new medication. Patients report higher satisfaction with information and increased self-efficacy regarding their medication use. Relevant for pharmacists looking to implement this service: focus on high-risk patients and involve the entire pharmacy team in the delivery. This is a result from the Make-It consortium in which our Division participates in implementing medication adherence interventions in clinical practice. #pharmacy #pharmaceuticalcare #medicationsafety #adherence #medicationadherence #MakeItconsortium Rik Ensing Ruby Janssen Ellen Koster Rob Heerdink

We are hiring! Are you an experienced pharmacoepidemiologist eager to advance your career in a dynamic and supportive environment? This position might be the perfect fit for you! Apply now to our vacancy! https://lnkd.in/dA_gs-q3

UPPER Stagebureau is op zoek naar een praktijkdocent poliklinische/openbare farmacie   Bij UPPER Stagebureau is een vacature beschikbaar voor een docent Coschappen poliklinische - openbare farmacie. Wij zijn hiervoor op zoek naar een apotheker die naast zijn/haar werkzaamheden in de apotheek het UPPER-stageteam wil komen versterken. Werkzaamheden bestaan o.a. uit het begeleiden van werkgroepbijeenkomsten en het beoordelen van coschapdossiers. Het betreft een deeltijdfunctie voor een halve dag per week. Over de concrete invulling (een halve dag/week, gespreid over de week of geclusterd) kan worden overlegd. Vind jij het leuk om jouw ervaring in te zetten om een belangrijke bijdrage te leveren aan het praktijkonderwijs binnen de opleiding tot apotheker reageer dan uiterlijk 6 januari.

We are hiring! Are you eager to advance Health Technology Assessment and drive cross-country, multi-stakeholder learning? Join our research team and play a key role in implementing the new EU Health Technology Assessment Regulation across three EU member states. Apply now to our vacancy! https://lnkd.in/eebKn8tZ

For conditionally authorised anticancer medicines more uncertainties remain than for fully authorised medicines. These uncertainties are meant to be addressed by additional, comprehensive, data collection. However, data from post-authorisation randomised controlled trials (RCTs) is frequently delayed, raising questions about the feasibility of these trials. In a recently study, Christine van Hattem and Amos de Jong explored factors that affect the feasibility of such post-authorisation RCTs by gathering perspectives from patients, physicians, medical ethicists, and pharmaceutical industry representatives. Their findings include that: - Taking into account the identified factors more explicitly when assessing trial recruitment and retention could strengthen regulatory feasibility assessments; - Trial designs should be tailored to the post-authorisation setting by including clinically relevant endpoints and a fair comparator; - Taking into account physicians’ and patients’ perceptions of uncertainties at the time of conditional marketing authorisation could improve their willingness to participate. Therefore, sponsors and regulators should better inform patients and physicians about the purpose and importance of post-authorisation RCTs, as well as the uncertainties that remain for conditionally authorised medicines. You can read the full study here: 🔗https://lnkd.in/d6aDrTVd Jolien de Groot Jarno Hoekman Esther Broekman Gabe Sonke Paula van Hennik Lourens Bloem

⏳ In less than two months, the EU HTA Regulation will come into effect, aiming to establish a more harmonized HTA framework in the EU. Last year, Utrecht University hosted the European Access Academy’s Spring Convention, bringing together key stakeholders in the field of HTA to identify and prioritize the remaining challenges and actionable steps for successful implementation of the Regulation. Findings from the pre-convention survey, which explored these challenges, have now been published in Health Policy and Technology. The survey highlighted national readiness for JCAs, HTA capacity limitations within Member States, and the feasibility of the proposed methodological framework as key challenges. Additionally, takeaways from the convention, published earlier this year in Health Research Policy and Systems, emphasized and prioritized the following action points: ⚖️ Assess the need and willingness to adjust Member State laws and health policy processes 📚 Ensure sufficient training and resources for all stakeholder groups 📝 Implement guidelines as living documents in collaboration with stakeholders 💡 Clarify the PICO identification process and its impact on JCAs For full insights, read the articles here: 🔗 https://lnkd.in/e278yTbu 🔗 https://lnkd.in/erP2j8PJ

Achieving a PhD with the distinction Cum Laude is a rare accomplishment, awarded only every few years. We feel incredibly fortunate to have had Amos de Jong as part of our division for the past four years. Beyond his outstanding research, Amos made invaluable contributions to teaching and fostering social cohesion. Thank you for being an exceptional team member, Amos! We wish you all the success in your new role.

Vandaag was het Make-It symposium op het Nivel. Acht proeftuinen hebben een therapietrouw interventie geïmplementeerd en vandaag maakten we de stand van zaken op. Rob Heerdink  bood een kennissynthese aan aan het Ministerie van VWS. Deze is over 2 weken breed beschikbaar! We hebben veel lessen geleerd uit het project.  Er is de afgelopen jaren veel gedaan. Zo hebben veel patiënten gesprekken gevoerd over hun medicatie met apotheekmedewerkers. Dat werd gewaardeerd. Dat is misschien wel het mooiste resultaat. Daarnaast leerden we over implementeren in de apotheeksetting. Het was een waardevolle ochtend waar ook veel contacten werden gelegd. Het is heel fijn te weten  dat we door kunnen. Volgend jaar starten er weer nieuwe proeftuinen.  Dank aan Menno van Woerkom voor de organisatie vanuit ons consortium. Aan Sandra Kruger-Peters voor haar bijdrage vanuit VWS en Caroline van de Steeg-van Gompel voor haar presentatie van de resultaten. En bovenal dank aan de proeftuinen!  Mark Slager, Marcel Kooij, Sander Borgsteede, Rik Ensing, Nitza Hooi, Ellen Van Loon, Erna Mombarg-Blankvoort en Bram Mertens En ook de overige Make-It leden: Marcia Vervloet, Ruby Janssen, Marle Gemmeke, Bart Van Den Bemt, Jacqueline Hugtenburg, Charlotte Bekker en Mirthe Oude Lansink Last but not least: ZonMw, dank voor de financiering!

The division is proud to share its achievements, awards, and contributions to society throughout 2023. We extend our heartfelt gratitude to our students and staff, who are the driving force behind these successes.

Thanks International Society for Pharmacoepidemiology for providing an excellent conference. We presented our research, participated in insightful discussions, and expanded our network with professionals from around the world. Hope to see you again next year!